Investing IdeasBrowse All StocksMarkets

Have your own idea? Try our Stock Screener

Header cover image

Swiss (SMI) Biotech Industry Analysis

UpdatedDec 30, 2024
DataAggregated Company Financials
Companies7
  • 7D6.7%
  • 3M13.4%
  • 1Y105.8%
  • YTD101.2%

Over the last 7 days, the Biotech industry has risen 6.7%, driven by gains from Kuros Biosciences of 9.7%. In the last 12 months, the industry was up 106%. Earnings are forecast to grow by 20% annually.

Industry Valuation and Performance

Has the Swiss Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 30 Dec 2024CHF 1.7bCHF 330.9m-CHF 87,805,465.002.4x-19.6x5.2x
Wed, 27 Nov 2024CHF 1.7bCHF 330.9m-CHF 85,899,131.001.6x-20.1x5.2x
Fri, 25 Oct 2024CHF 1.8bCHF 333.1m-CHF 82,023,629.001.7x-22.4x5.5x
Sun, 22 Sep 2024CHF 1.6bCHF 333.6m-CHF 81,088,264.001.8x-19.9x4.8x
Tue, 20 Aug 2024CHF 1.4bCHF 319.7m-CHF 142,008,264.001.9x-10x4.4x
Thu, 18 Jul 2024CHF 777.0mCHF 151.7m-CHF 146,197,264.001.6x-5.3x5.1x
Sat, 15 Jun 2024CHF 756.0mCHF 151.7m-CHF 146,197,264.001.6x-5.2x5x
Mon, 13 May 2024CHF 504.5mCHF 170.9m-CHF 134,976,548.281x-3.7x3x
Wed, 10 Apr 2024CHF 393.5mCHF 67.4m-CHF 173,183,885.980.1x-2.3x5.8x
Fri, 08 Mar 2024CHF 352.2mCHF 55.5m-CHF 173,256,243.720.4x-2x6.4x
Sun, 04 Feb 2024CHF 383.4mCHF 317.7m-CHF 175,969,075.000.9x-2.2x1.2x
Tue, 02 Jan 2024CHF 280.1mCHF 317.2m-CHF 176,170,214.000.6x-1.6x0.9x
Thu, 30 Nov 2023CHF 310.1mCHF 318.0m-CHF 210,476,600.00n/a-1.5x1x
Sat, 28 Oct 2023CHF 241.2mCHF 318.5m-CHF 211,264,509.00n/a-1.1x0.8x
Mon, 25 Sep 2023CHF 271.2mCHF 318.7m-CHF 219,376,328.00n/a-1.2x0.9x
Wed, 23 Aug 2023CHF 504.3mCHF 328.1m-CHF 177,084,182.00n/a-2.8x1.5x
Fri, 21 Jul 2023CHF 326.5mCHF 321.8m-CHF 179,865,287.00n/a-1.8x1x
Sun, 18 Jun 2023CHF 316.3mCHF 329.5m-CHF 180,747,483.00n/a-1.8x1x
Tue, 16 May 2023CHF 356.7mCHF 329.7m-CHF 183,040,239.00n/a-1.9x1.1x
Thu, 13 Apr 2023CHF 349.7mCHF 482.5mCHF 12.4m1.6x28.1x0.7x
Sat, 11 Mar 2023CHF 464.5mCHF 494.3mCHF 15.0m1.6x31x0.9x
Mon, 06 Feb 2023CHF 501.6mCHF 493.4mCHF 14.5m1.7x34.6x1x
Wed, 04 Jan 2023CHF 501.2mCHF 493.4mCHF 14.5m1.7x34.6x1x
Fri, 02 Dec 2022CHF 528.8mCHF 493.4mCHF 14.5m1.9x36.5x1.1x
Sun, 30 Oct 2022CHF 504.5mCHF 508.7mCHF 14.9m1.8x34x1x
Tue, 27 Sep 2022CHF 505.1mCHF 508.3mCHF 15.9m1.8x31.8x1x
Thu, 25 Aug 2022CHF 502.3mCHF 488.6mCHF 36.1m1.8x13.9x1x
Sat, 23 Jul 2022CHF 525.6mCHF 489.3mCHF 42.2m1.8x12.4x1.1x
Mon, 20 Jun 2022CHF 517.9mCHF 458.5mCHF 81.3m2x6.4x1.1x
Wed, 18 May 2022CHF 706.7mCHF 475.9mCHF 25.8m2x27.4x1.5x
Fri, 15 Apr 2022CHF 1.1bCHF 291.0m-CHF 142,651,482.001.9x-7.7x3.8x
Sun, 13 Mar 2022CHF 1.3bCHF 283.5m-CHF 140,870,089.002x-9x4.5x
Tue, 08 Feb 2022CHF 5.1bCHF 318.4m-CHF 658,886,768.001.8x-7.7x16x
Thu, 06 Jan 2022CHF 4.4bCHF 316.6m-CHF 659,138,475.002x-6.7x14x
Price to Earnings Ratio

-6.7x


Total Market Cap: CHF 4.4bTotal Earnings: -CHF 659,138,475.00Total Revenue: CHF 316.6mTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Biotech Industry Price to Earnings3Y Average 4.2x20232024
Current Industry PE
  • Investors are optimistic on the Swiss Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 3.1x is lower than the industry's current PS ratio of 5.2x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since losses are shrinking while sales have been flat.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.11%
Healthcare1.68%
Biotech6.72%
Biotech6.72%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
KURN Kuros BiosciencesCHF 21.355.7%
+CHF 43.2m		511.7%PS15.3x
SANN Santhera Pharmaceuticals HoldingCHF 13.8220.8%
+CHF 28.8m		40.9%PE2.7x
IDIA IdorsiaCHF 0.8212.6%
+CHF 17.3m		-61.1%PS2.1x
BSLN Basilea PharmaceuticaCHF 41.350.5%
+CHF 2.4m		17.1%PS3.4x
RLF Relief Therapeutics HoldingCHF 4.212.7%
+CHF 1.4m		111.6%PS6.1x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlans & PricingLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseWhat's New
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

SANN

CHF 13.82

Santhera Pharmaceuticals Holding

7D

20.8%

1Y

40.9%

ADXN

CHF 0.057

Addex Therapeutics

7D

-1.0%

1Y

24.3%

IDIA

CHF 0.82

Idorsia

7D

12.6%

1Y

-61.1%

Improved Revenues Required Before Idorsia Ltd (VTX:IDIA) Stock's 71% Jump Looks Justified

Dec 19
Improved Revenues Required Before Idorsia Ltd (VTX:IDIA) Stock's 71% Jump Looks Justified

RLF

CHF 4.21

Relief Therapeutics Holding

7D

2.7%

1Y

111.6%

KURN

CHF 21.35

Kuros Biosciences

7D

5.7%

1Y

511.7%

Kuros Biosciences AG's (VTX:KURN) 27% Share Price Plunge Could Signal Some Risk

Dec 13
Kuros Biosciences AG's (VTX:KURN) 27% Share Price Plunge Could Signal Some Risk

MOLN

CHF 4.06

Molecular Partners

7D

-12.3%

1Y

18.0%

BSLN

CHF 41.35

Basilea Pharmaceutica

7D

0.5%

1Y

17.1%